Related Experiment Video
Updated: May 7, 2026
04:15
A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
How natalizumab binds and antagonizes α4 integrins
Yamei Yu1, Thomas Schürpf1, Timothy A Springer1
1From the Program in Cellular and Molecular Medicine, Children's Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115.
The Journal of Biological Chemistry
|September 20, 2013
Summary
Natalizumab, a therapy for multiple sclerosis and Crohn's disease, targets α4-integrins. Its binding site, distinct from the ligand-binding groove, reveals novel antagonism mechanisms.
Area of Science:
- Immunology
- Structural Biology
- Pharmacology
Background:
- Natalizumab is a therapeutic antibody targeting α4-integrins, crucial in inflammatory diseases like multiple sclerosis and Crohn's disease.
- Understanding the precise binding interactions of natalizumab with α4-integrins is key to elucidating its therapeutic mechanism and potential for drug development.
Purpose of the Study:
- To determine the structural basis of natalizumab binding to α4-integrins.
- To investigate the mechanism of antagonism between natalizumab and vascular cell adhesion molecule (VCAM) binding.
- To analyze species-specific differences in α4-integrin epitopes and their implications for antibody design.
Main Methods:
- Crystal structure determination of natalizumab Fab fragment bound to an α4 integrin domain.
- Competitive binding assays between natalizumab and VCAM for α4β1 integrin.
- Molecular docking simulations to model VCAM-integrin interactions.
- Mapping of species-specific differences onto α4β1 and α4β7 integrin structures.
Main Results:
- The crystal structure revealed natalizumab binds to differences on the β-propeller domain circumference, outside the VCAM ligand-binding groove.
- Natalizumab exhibits noncompetitive antagonism of VCAM binding to α4β1 integrin.
- Docking models suggest VCAM binding is unimpeded by natalizumab, but requires conformational changes in VCAM for subsequent binding.
- Ligand-binding sites of α4β1 and α4β7 integrins are highly conserved across species, while epitopes targeted by natalizumab exploit conserved differences.
Conclusions:
- Natalizumab's mechanism of action involves binding to a distinct epitope, leading to noncompetitive antagonism of VCAM-mediated cell adhesion.
- Exploiting species-specific differences away from conserved ligand-binding sites offers a strategy for developing novel therapeutic antibodies with unanticipated mechanisms.
Related Concept Videos
01:10Integrins
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:31Immunoglobulin-like Cell Adhesion Molecules
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:41Affinity and Avidity
Overview